このエントリーをはてなブックマークに追加
ID 50694
フルテキストURL
著者
Tsutsumi, Koichiro Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol
Kawamoto, Hirofumi Kawasaki Med Univ, Dept Gen Internal Med 2
Hirao, Ken Hiroshima City Hosp, Dept Internal Med
Sakakihara, Ichiro Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol
Yamamoto, Naoki Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol
Noma, Yasuhiro Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol
Fujii, Masakuni Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol
Kato, Hironari Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol
Ogawa, Tsuneyoshi Hiroshima City Hosp, Dept Internal Med
Ishida, Etsuji Kurashiki Cent Hosp, Dept Gastroenterol & Hepatol
Kuwaki, Kenji Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol
Nouso, Kazuhiro Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol
Okada, Hiroyuki Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol
Yamamoto, Kazuhide Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol
抄録
Background: Measurement of objective response to chemotherapy using imaging modalities is sometimes difficult in pancreatic cancer (PC). We aimed to verify whether monitoring of serum tumor markers (TMs), namely carcinoembryonic antigen, CA19-9, DUPAN-2, SPan-1, can facilitate earlier confirmation of treatment failure. Methods: Monitoring of serum TMs and computed tomography were performed every 4 weeks until progression of disease in 90 patients with PC undergoing gemcitabine therapy. In Group A (January 2006 October 2007), we analyzed the fluctuation rates of TMs with high pretreatment positive rates, and defined the criteria of progressive disease under TM monitoring (TM-PD). In Group B (November 2007 October 2008), we calculated the time to progression (TTP) under this TM-PD criteria, which was compared with the UP under the RECIST criteria. Results: CA19-9 and SPan-1 had the highest pretreatment positive rates: 83% and 90%, respectively. In Group A (CA19-9, n = 38; SPan-1, n = 36), TM-PD criteria were defined as follows: fluctuation rates were >25% for a month or >= 10% for 2 consecutive months in CA19-9, and >= 10% for a month in SPan-1. In Group B (CA19-9, n = 18; SPan-1, n = 17), under these criteria, one-month earlier confirmation of treatment failure was feasible in 61% by CA19-9 and 59% by SPan-1. Furthermore, the combination could facilitate this determination in 72% (35/49), significantly better than CA19-9 alone (P = 0.004). Conclusion: Monitoring of serum CA19-9 and Span-1 is helpful for earlier confirmation of treatment failure during gemcitabine therapy in PC.
キーワード
Pancreas
Pancreatic cancer
Tumor marker
Gemcitabine
Diagnosis
発行日
2012-09
出版物タイトル
Pancreatology
12巻
5号
出版者
Karger
開始ページ
409
終了ページ
416
ISSN
1424-3903
資料タイプ
学術雑誌論文
オフィシャル URL
http://dx.doi.org/10.1016/j.pan.2012.07.009
関連URL
http://ousar.lib.okayama-u.ac.jp/metadata/50663
言語
English
OAI-PMH Set
岡山大学
著作権者
Copyright (C) 2012, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt. Ltd. All rights reserved.
論文のバージョン
author
査読
有り
DOI
Web of Sience KeyUT